Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Apyx Medical (APYX) over the last 16 years, with Q3 2025 value amounting to $57.4 million.

  • Apyx Medical's Liabilities and Shareholders Equity fell 552.69% to $57.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.6 million, marking a year-over-year decrease of 1286.32%. This contributed to the annual value of $64.8 million for FY2024, which is 1817.01% down from last year.
  • Apyx Medical's Liabilities and Shareholders Equity amounted to $57.4 million in Q3 2025, which was down 552.69% from $58.2 million recorded in Q2 2025.
  • In the past 5 years, Apyx Medical's Liabilities and Shareholders Equity ranged from a high of $79.2 million in Q4 2023 and a low of $51.8 million during Q4 2022
  • For the 5-year period, Apyx Medical's Liabilities and Shareholders Equity averaged around $63.3 million, with its median value being $62.4 million (2023).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 2465.91% in 2022, then surged by 5304.68% in 2023.
  • Apyx Medical's Liabilities and Shareholders Equity (Quarter) stood at $68.7 million in 2021, then decreased by 24.66% to $51.8 million in 2022, then soared by 53.05% to $79.2 million in 2023, then decreased by 18.17% to $64.8 million in 2024, then dropped by 11.53% to $57.4 million in 2025.
  • Its last three reported values are $57.4 million in Q3 2025, $58.2 million for Q2 2025, and $60.2 million during Q1 2025.